



for **immunotherapies & innovations**
for Infectious Diseases

8th Edition – 27 & 28 November 2024 - Lyon, France



LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK



mabdesign
THE BIOTHERAPY EXPERT

Post-Event Report

I4ID LAST EDITIONS

The emergence of new infectious diseases, the re-emergence of “old” infectious diseases, the rise of antibacterial resistance and the difficulty to come out with a new pipeline of new antimicrobial compounds leads to consider the potential of non-conventional approaches, such as immunotherapies as new therapies.

Already on the seventh edition, the **I4ID congress** started on 2017 and the aim was to develop an exclusive conference dedicated to immunotherapies and infectious diseases, something that never existed before. In 2019, The thematic was enlarged to include, with the immunotherapies, all the innovations being developed to fight infectious diseases. Last year, regarding the unique sanitary situation we were going through, we had decided it was imperative to include on this edition program the COVID-19 thematic.

I4ID is co-organized by **MabDesign**, the association who the aim is to support and federate the french industrial sector of biotherapy (www.mabdesign.fr) and **Lyonbiopôle**, the healthcare cluster of the Auvergne-Rhône-Alpes region (<https://lyonbiopole.com>). These two emblematic health stakeholders have brought together, for two days, experts from around the world to combine approaches and strengths to innovate in the fields of infectious diseases and immunotherapy.

From 2017



1800+ attendees



290+

High-profile
speakers



1490+

B2B meetings

FOCUS IN 2024



The **I4ID2024** program included 4 tracks with keynote lectures, pitch talks and industrial talks covering the latest developments and highest innovative projects in the field. Furthermore, it was possible to set up, through an online platform, business meetings during both days (partnering).



The topics covered during this congress were:

- Alternatives to current antibiotics
- Immunotherapies & new biotherapeutics
- Latest developments in vaccines
- Diagnostic, prognostic and theragnostic biomarkers

WHO ATTENDED IN 2024?

KEY FIGURES

- ✓ 280+ participants from different countries
- ✓ 120+ different organizations present
- ✓ 250+ BtoB meetings took place
- ✓ 29 High-profile Speakers
- ✓ 20+ Sponsors & Exhibitors



WHO ATTENDED IN 2024?

COMPANIES WHICH ATTENDED :

Adamastor Bioservices | Affilogic | Africa Health Research Institute (AHRI) | Agence de l'Innovation en Santé / SGPI | Agilent Technologies | Ailurus Bio | AIS Biotech | AltraBio | ANRS MIE | AQUITAINE SCIENCE TRANSFERT | Asymchem | Aurobac Therapeutics | Axfen Bio | BE4S | BECKMAN COULTER LIFE SCIENCES | Bioaster | BioKryo | BioLizard | bioMérieux | Biotech Voyager Consulting | BIOTEM | Biozentrum - University of Basel | Boehringer Ingelheim Animal Health | CAPEVAL PHARMA | CeGa | Centauri Therapeutics | Centre International de Recherche en Infectiologie (CIRI) | Certara | Charles River Laboratories | CHU AMIENS PICARDIE | CONSULTYS | Cortez Bio-consulting | Croda | CSafe | CYNBIOSE | Cytiva | CytobodX | Dynamic Biosensors GmbH | Ecole Normale Supérieure de Lyon | MOLSID | Epynext Therapeutics | ERBC – Voxcan | Eurofins ADME Bioanalyses | Evotec | Expres2ion biotech | Fabentech | Fagoterapia Lab | Firalis Molecular Precision | GenScript Biotech | GRIPA | GSK Vaccines | GTP Bioways | Hormae Pharma | Hospices Civils de Lyon | ICTA PM | Imcyse | Imperial college London | Innovative Diagnostics | INSERM ANRS MIE PARIS | Institut Pasteur | IRBA | KYMOS GROUP S.L. | LA GAZETTE DU LABORATOIRE | Lemba Therapeutics | LICORbio | LimmaTech Biologics AG | London school of Hygiene & Tropical Medicine | Luxembourg Institute of Health | Lyonbiopôle | MabDesign | Mabsilico | Manpower Life Science | MCE CARREL Avocats | Meddenovo Drug Design | Métropole de Lyon | MGI TECH GMBH | MICHADVICES | MicroOmix | Molsid | National Reference Center for respiratory infections virus | New England Biolabs France | NewCo | Nexomis | NG Biotech | Obulytix | Olink Proteomics AB | ONCODESIGN SERVICES | OnlyLyon Invest | Osivax | OSTA THERAPEUTICS | PEPperPRINT GmbH | Pfizer | PhaRMRapH | Promega | Pulsalys | RD-BIOTECH | Roche | Sanofi | Service économique de l'Etat en région AURA – DREETS | SGS Vitrology | SMALTIS | SpikImm | ULTRace Development Partner | StromaCare | SupBiotech | Takis | Texcell | Turing Biosystems | Unither Pharmaceuticals | Université catholique de Lyon | University Hospital of Cologne | University of Münster | University of Pisa | Valneva | Vaxinano | VaxxCellence | Vaxxel | Vetophage | Vetoquinol SA | VIBIOSPHEN | Virnext | White Raven | World Courier | World Health Organization (WHO) | WuXi AppTec

AGENDA

Day 1 – November 27th


08:30	Registration & welcome coffee - <i>Exhibition hall</i>
09:10	Welcome Address
	Opening lectures Chaired by Daniel Laroque, Sanofi
09:15	<i>Discovery and Characterization of Zosurabalpin</i> by Claudia Zampaloni - Roche, Switzerland
09:45	<i>Systems-level analyses of human immunity</i> by Petter Brodin - Imperial college London, United Kingdom & Karolinska Institute, Sweden
10:15	Coffee break - B2B meetings - <i>Exhibition hall</i>
	Track 1: Alternatives to current antibiotic Chaired by Francesca Bernardini, Evotec & Sébastien Coyne, Aurobac
10:45	<i>Application of phage therapy in infectious diseases</i> by Giuseppe Maccari - Toscana Life Sciences & Fagoterapia LAB, Italy
11:05	<i>A Human Lung Tissue Model to Study - Pseudomonas aeruginosa Infection and Treatment</i> by Urs Jenal - Biozentrum & University of Basel, Switzerland
11:25	<i>Phage lysins for transformative innovation of the antibiotics market</i> by Yves Briers - Obulytix, Belgium
11:45	Q&A session
12:00	Lunchbreak - B2B meetings - <i>Exhibition hall</i>
	Track 2: Immunotherapies & new biotherapeutics Chaired by Robbert van der Most, VaxxCequence & Cyril Guyard, Bioaster
14:00	<i>Broad spectrum biotherapies for emergency preparedness</i> by Caroline Ballet - Fab'entech, France
14:20	<i>The potential of broadly neutralizing antibodies to prevent and treat HIV-1 infection</i> by Florian Klein - University Hospital of Cologne, Germany
14:40	<i>Breaking new ground - targeting the gut microbiota in systemic autoimmunity</i> by Carina Brune - University of Münster, Germany
15:00	<i>Targeting Long Non-Coding RNAs with Antisense Oligonucleotides to Enhance Vaccine Response</i> by Stéphanie Fanucchi - Lemba Therapeutics, Netherlands
15:20	<i>Insights into the in vivo mode of action of mono- and bispecific antibodies through kinetic analysis of affinity and avidity</i> by Anahí Higuera-Rodríguez - Dynamic Biosensors, Germany
15:35	Q&A session
15:50	Coffee break - B2B meetings - <i>Exhibition hall</i>
	Breakthrough innovation Session Chaired by Fabienne Venet, Hospices Civils de Lyon & Mélanie Denizot, Lyonbiopôle
16:30	<i>The Vaccine Architect: Designing Antigen with Immunological Blueprints</i> by Coline Sivelles & Vincent Pavot - Sanofi, France
16:50	<i>Exploiting the Complement system for directed therapy against Pseudomonas aeruginosa infections</i> by Aubin Pitiot - Luxembourg Institute of Health, France
17:00	<i>Development of novel genetic vaccine platforms for epidemic preparedness: from the idea to GMP production</i> by Antonella Comforti - Takis Biotech, Italy
17:10	<i>New antigenic urinary assay for BK polyomavirus</i> by Etienne Brochet - CHU Amiens, France
17:20	<i>New approaches for diagnosis and therapy by phage proteins</i> by Mai Huong Chatain - Vetophage, France
17:30	<i>The Cochlin LCCL Domain: A Novel Therapeutic Agent for Enhancing Host Innate Immunity during infection through Efferocytosis</i> by Louise Courcol - CIRI, France
17:40	<i>Generation of a pan-specific anti-human influenza A Nanofitin for direct protective effect in respiratory tract</i> by Perrine Jacquot - Affilogics, France
17:50	<i>Better antibodies against membrane proteins thanks to recombinant extracellular vesicles</i> by Vincent Delauzun - Cytobodx, France
18:00	End of DAY 1

AGENDA

Day 2 – November 28th

09:00	Welcome coffee Opening lectures Chaired by Nadia Khelef, Pasteur Institute
09:30	<i>Progress in TB vaccine discovery and development</i> by Willem Hanekom - Africa Health Research Institute (AHRI), South Africa
10:00	<i>Shifts in pandemic medical countermeasures – Global Preparedness Monitoring Board</i> by Sylvie Briand - Pandemic and Epidemic Diseases Department at the World Health Organization (WHO), France
10:30	Coffee break - B2B meetings - Exhibition hall
	Track 3 : Latest developments in vaccines Chaired by Daniel Larocque, Sanofi & Behazine Combadière, Sanofi
11:00	<i>General view of latest vaccine developments by Sanofi and early stage immunology research</i> by Behazine Combadière - Sanofi, France
11:30	<i>Advances in Immunological Memory: The Role of β-Glucan in Innate Immune Modulation</i> by Jessica Quintin - Institut Pasteur, France
11:50	<i>Development of the single-shot chikungunya vaccine IXCHIQ</i> by Martina Schneider - Valneva, France
12:10	Q&A session
12:25	Lunchbreak - B2B meetings - Exhibition hall
	Track 3 : Latest developments in vaccines Chaired by Lionel Cupillard, Boehringer Ingelheim Animal Health
14:00	<i>Latest results for Metavac®-RSV, a mucosal bivalent live attenuated vaccine</i> by Julia Dubois - CIRI, France
14:20	<i>A Novel Vaccine Against Neisseria gonorrhoea Preparedness & reactivity in the development of a new Blue Tongue Virus vaccine</i> by H�el�ene Gaude - Boehringer Ingelheim Animal Health, France
14:40	<i>A Novel Vaccine Against Neisseria gonorrhoea</i> by Michael Kowarik - Limmatech, Switzerland
15:00	Q&A session
	Track 4 : Diagnostic Prognostic and theragnostic Biomarkers Chaired by Nadia Khelef, Pasteur Institute
15:15	<i>How a multiplex lateral flow immunoassay is helping clinicians worldwide combat antimicrobial resistance</i> by Milovan Stankov-Pug�es - NG Biotech, France
15:35	<i>Unveiling Immune Insights: The Crucial Role of Immune Functional Assays (IFA) in Immunomonitoring</i> by William Mouton - HCL, France
15:55	Q&A session
16:10	Announcement of next year edition
16:20	End of CONGRESS

SCIENTIFIC ADVISORY BOARD



2024 SPONSORS

Platinum Sponsor

sanofi

Silver Sponsor




**Boehringer
Ingelheim**

dynamic
BIOSENSORS

Bronze Sponsors



Agilent Technologies



evotec



KYMOS
GROUP

2024 EXHIBITORS



Supported by




2024 PARTNERS

Institutional partners



Media partners





I4ID



immunotherapies & innovations
for **infectious Diseases**

9th Congress 2025

November 2025 – LYON, FRANCE

For more information,
Please contact Laure Delhon – MabDesign at:
laure.delhon@mabdesign.fr or tel. +33 (0)7 69 85 65 56

Follow Us



I4IDCongress



I4IDcongress

#I4ID2025